Chief scientist Jakub Pachocki said it won’t be long until artificial intelligence models can also improve themselves without ...

Forecasts of explosive AI progress predict that what researchers call recursive self-improvement is on the horizon.  But a ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

AbCellera Biologics (ABCL) stock and other AI-driven healthcare companies rise as the FDA plans to create a new deputy ...

Short interest data from late August 2026 highlights deeply divided investor sentiment across small- and mid-cap healthcare ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

OpenClaw 2.0: el agente personal deja de ser personal Un harness es la capa de software que envuelve a un modelo de lenguaje ...

Головний науковець OpenAI Якуб Пачоцкі виступив із попередженням про небезпеку надто швидкого розвитку штучного інтелекту, ...